15 Jul 2015 07:00
Premaitha Health plc
Grant of Options
Manchester, UK - 15 July 2015: Premaitha Health plc ("Premaitha" or "the Company"; AIM: NIPT) announces that, on 14 July 2015, the Company granted options over 5,500,000 ordinary shares in the Company to certain directors and employees, as set out in the table below.
| Number of existing options | Number of options granted
| Total options held |
Stephen Little | 10,555,984 | 1,500,000 | 12,055,984 |
Barry Hextall | - | 1,000,000 | 1,000,000 |
Employees / senior management | 11,769,638 | 3,000,000 | 14,769,638 |
2,833,334 of the options were granted under the Company's EMI option scheme; the balance of 2,666,666 options have been granted under the Company's unapproved option scheme. All of these options have an exercise price of 20 pence per share.
Vesting conditions of all of the options issued under the Company's EMI and unapproved schemes are that: (i) options only vest if there is a positive movement in earnings per share; and (ii) options become exercisable in respect of one third of the ordinary shares over which they are granted on the first, second and third anniversaries of the original date of grant. The expiry of the vesting period in respect of these options is 14 July 2025.
Following the grant of options, the total number of options in issue is 35,988,332, representing approximately 15.8 per cent. of the current issued share capital of the Company.
The issued share capital of the Company comprises 228,163,709 ordinary shares of 10 pence each.
For more information, please contact: |
|
|
|
Premaitha Health plcDr Stephen Little, Chief Executive Officer Jo Cross, Head of Marketing | Tel: +44 (0) 161 667 6865Email: investors@premaitha.com joanne.cross@premaitha.com
|
Cairn Financial Advisers LLP (NOMAD)Liam Murray / Avi Robinson
| Tel: +44 (0) 20 7148 7900 |
Panmure Gordon (UK) Limited (Broker)Robert Naylor / Freddy Crossley /Maisie Rose Atkinson
| Tel: +44 (0) 20 7886 2500 |
Instinctif Partners (Media)Melanie Toyne Sewell / Jen Lewis /Emma Barlow | Tel: +44 (0) 207 457 2020 Email: premaitha@instinctif.com |
About Premaitha Health
Premaitha is an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for non-invasive prenatal screening (NIPT) and other applications. Premaitha's flagship product, the IONA® test is the first non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer CE-marked NIPT in-house for the first time.
The IONA® test estimates the risk of a fetus having Down's syndrome or other serious genetic diseases. The IONA® test has a higher detection rate and lower false positive rate than existing screening tests, giving pregnant women, their families and their doctors greater confidence in the result and reducing the need for unnecessary invasive follow-up tests and the associated anxiety and stress. The IONA® test is a complete diagnostic system that is simple and standardised, enabling Premaitha's clinical laboratory customers to perform the test in their own facilities. This supports Premaitha's strategy of accelerating the broad dissemination of NIPT tests to ensure that their benefits are available to pregnant women everywhere.
Premaitha is listed on the London Stock Exchange (AIM). Its R&D, manufacturing and commercial operation is located at Manchester Science Park, UK. For further information please visit www.premaitha.com or email iona@premaitha.com.
YGEN.L (YGEN)